Brookstone Capital Management Has $32.56 Million Stock Position in Eli Lilly and Company $LLY

Brookstone Capital Management lifted its stake in Eli Lilly and Company (NYSE:LLY) by 15.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,767 shares of the company’s stock after acquiring an additional 5,471 shares during the period. Brookstone Capital Management’s holdings in Eli Lilly and Company were worth $32,559,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Phillips Financial Management LLC grew its stake in shares of Eli Lilly and Company by 6.1% in the second quarter. Phillips Financial Management LLC now owns 1,301 shares of the company’s stock worth $1,015,000 after acquiring an additional 75 shares during the last quarter. Jacobsen Capital Management grew its stake in shares of Eli Lilly and Company by 15.9% in the second quarter. Jacobsen Capital Management now owns 1,563 shares of the company’s stock worth $1,218,000 after acquiring an additional 214 shares during the last quarter. FNY Investment Advisers LLC grew its stake in shares of Eli Lilly and Company by 441.9% in the second quarter. FNY Investment Advisers LLC now owns 1,138 shares of the company’s stock worth $887,000 after acquiring an additional 928 shares during the last quarter. Chokshi & Queen Wealth Advisors Inc grew its stake in shares of Eli Lilly and Company by 9.5% in the second quarter. Chokshi & Queen Wealth Advisors Inc now owns 1,036 shares of the company’s stock worth $807,000 after acquiring an additional 90 shares during the last quarter. Finally, D.A. Davidson & CO. lifted its position in Eli Lilly and Company by 5.0% in the second quarter. D.A. Davidson & CO. now owns 46,111 shares of the company’s stock worth $35,945,000 after purchasing an additional 2,211 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. JPMorgan Chase & Co. reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. Morgan Stanley cut their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Finally, HSBC lifted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $938.61.

Insider Transactions at Eli Lilly and Company

In other news, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jamere Jackson acquired 200 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $799.85 on Wednesday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The firm has a market cap of $757.03 billion, a PE ratio of 52.28, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business has a fifty day moving average of $759.77 and a 200-day moving average of $766.43.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $3.92 earnings per share. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.